Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study
DOI:
https://doi.org/10.2340/1651-226X.2025.44003Keywords:
Early breast cancer, receptors, estrogen, female, real-world, outcome, adjuvant cyclin-dependent kinasesAbstract
Background: While adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) have improved invasive disease-free survival (iDFS) in ER-positive, HER2-negative early breast cancer (EBC) in the MonarchE and NATALEE trials, their real-world applicability in Denmark remains unclear. This study evaluates Danish patients meeting comparable high-risk criteria and their outcomes, hypothesizing that a substantial proportion could benefit from additional adjuvant treatment options.
Methods: Patients with ER-positive, HER2-negative EBC, diagnosed 2014–2019, who met MonarchE and/or NATALEE eligibility, were included and categorized as intermediate or high risk corresponding to trial definitions. Outcomes were overall survival (OS), iDFS, cumulative incidence of distant recurrence-free survival (DRFS) events and endocrine therapy adherence.
Results: Of all new cases of EBC, approximately 31% were included. Of 5,788 patients, 59.1% were intermediate risk and 40.9% high risk. Five-year OS and iDFS were lower in high-risk than intermediate-risk patients (84.5% vs. 91.9% and 76.2% vs. 85.7%, respectively), and cumulative DRFS event rates were higher (18.5% vs. 8.9%). High-risk patients more often received chemotherapy, yet nonchemotherapy subgroups in both risk categories had worse outcomes. Endocrine therapy adherence at 5 years was 77%.
Interpretation: A considerable proportion of Danish EBC patients meet high-risk criteria similar to CDK4/6 inhibitor trial populations and experience inferior outcomes despite standard therapy of antihormone treatment +/- chemotherapy. Our real-world data underscore the need for more effective and less toxic adjuvant therapies such as CDK4/6 inhibitors.
Downloads
References
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol Off J Am Soc Clin Oncol. 2020 Dec 1;38(34):3987–98.
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol Off J Eur Soc Med Oncol. 2021 Dec;32(12):1571–81.
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol Off J Eur Soc Med Oncol. 2025 Feb;36(2):149–57.
https://doi.org/10.1016/j.annonc.2024.10.015 DOI: https://doi.org/10.1016/j.annonc.2024.10.015
Fasching PA, Stroyakovskiy D, Yardley D, Huang CS, Crown JP, Bardia A, et al. LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Ann Oncol. 2024 Sept;35:S1207.
https://doi.org/10.1016/j.annonc.2024.08.2251 DOI: https://doi.org/10.1016/j.annonc.2024.08.2251
Jensen MB, Torpe E, Teunissen Z, Taarnhøj G, Brix E, Knoop A, et al. Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group. Lancet Oncol. 2025 May;26(5):654–62.
https://doi.org/10.1016/S1470-2045(25)00085-3 DOI: https://doi.org/10.1016/S1470-2045(25)00085-3
Martín M, Carrasco E, Rodríguez-Lescure Á, Andrés R, Servitja S, Antón A, et al. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry. Breast Cancer Res Treat. 2023 Sept;201(2):151–9.
https://doi.org/10.1007/s10549-023-07002-1 DOI: https://doi.org/10.1007/s10549-023-07002-1
Kanjanapan Y, Anderson W, Smith M, Green J, Chalker E, Craft P. Real-world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors. Clin Breast Cancer. 2025 Feb;25(2):e159–69.e2.
https://doi.org/10.1016/j.clbc.2024.08.022 DOI: https://doi.org/10.1016/j.clbc.2024.08.022
Nelson DR, Brown J, Morikawa A, Method M. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. Wang Y, editor. PLoS One. 2022 Feb 25;17(2):e0264637.
https://doi.org/10.1371/journal.pone.0264637 DOI: https://doi.org/10.1371/journal.pone.0264637
Lammers SWM, Meegdes M, Vriens IJH, Voogd AC, De Munck L, Van Nijnatten TJA, et al. Treatment and survival of patients diagnosed with high-risk HR+/HER2− breast cancer in the Netherlands: a population-based retrospective cohort study. ESMO Open. 2024 May;9(5):103008.
https://doi.org/10.1016/j.esmoop.2024.103008 DOI: https://doi.org/10.1016/j.esmoop.2024.103008
Liu X, Binicy B, Acs B, Eriksson Bergman L, Loibl S, Gnant M, et al. Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study. Lancet Reg Health – Eur. 2025 Dec;59:101471.
https://doi.org/10.1016/j.lanepe.2025.101471 DOI: https://doi.org/10.1016/j.lanepe.2025.101471
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet Lond Engl. 2005 Jan 1;365(9453):60–2.
https://doi.org/10.1016/S0140-6736(04)17666-6 DOI: https://doi.org/10.1016/S0140-6736(04)17666-6
Breast International Group (BIG) 1–98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747–57.
https://doi.org/10.1056/NEJMoa052258 DOI: https://doi.org/10.1056/NEJMoa052258
Salvo EM, Ramirez AO, Cueto J, Law EH, Situ A, Cameron C, et al. Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Breast Edinb Scotl. 2021 June;57:5–17.
https://doi.org/10.1016/j.breast.2021.02.009 DOI: https://doi.org/10.1016/j.breast.2021.02.009
Early Breast Cancer Trialists’ Collaborative Group. Electronic address: bc.overview@ctsu.ox.ac.uk. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. Lancet Lond Engl. 2024 Oct 12;404(10461):1407–18.
https://doi.org/10.1016/S0140-6736(24)01745-8 DOI: https://doi.org/10.1016/S0140-6736(24)01745-8
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet Lond Engl. 2013 Mar 9;381(9869):805–16.
Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013 June 20;31(18_suppl):5.
https://doi.org/10.1200/jco.2013.31.18_suppl.5 DOI: https://doi.org/10.1200/jco.2013.31.18_suppl.5
Gray R, Early Breast Cancer Trialists’ Collaborative Group. Abstract GS3-03: effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women. Cancer Res. 2019 Feb 15;79(4_Supplement):GS3-03.
https://doi.org/10.1158/1538-7445.SABCS18-GS3-03 DOI: https://doi.org/10.1158/1538-7445.SABCS18-GS3-03
Torpe M, Berg T, Jensen M, Ejlertsen B. Compliance with endocrine therapy among breast cancer survivors. Dan Med J. 2024;71(12):9. DOI: https://doi.org/10.61409/A05240316
Ejlertsen B, Jensen MB, Mouridsen HT, Danish Breast Cancer Cooperative Group. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol Stockh Swed. 2014 Feb;53(2):174–85.
https://doi.org/10.3109/0284186X.2013.850738 DOI: https://doi.org/10.3109/0284186X.2013.850738
Harbeck N, Gluz O, Christgen M, Nitz UA, Braun M, Thill MAM, et al. 189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial. ESMO Open. 2025 May;10:104743.
https://doi.org/10.1016/j.esmoop.2025.104743 DOI: https://doi.org/10.1016/j.esmoop.2025.104743
Kahraman S, Hizal M, Demirel BC, Guven DC, Gumusay O, Uluc BO, et al. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study. BMC Cancer. 2024 Dec 30;24(1):1592.
https://doi.org/10.1186/s12885-024-13357-5 DOI: https://doi.org/10.1186/s12885-024-13357-5
Celik A, Dahl LS, Garly R, Glavicic V, Sharma MB, Yammeni S, et al. Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study. Acta Oncol Stockh Swed. 2025 June 11;64:778–83.
https://doi.org/10.2340/1651-226X.2025.43226 DOI: https://doi.org/10.2340/1651-226X.2025.43226
Chamalidou C, Nasic S, Linderholm B. Compliance to adjuvant endocrine therapy and survival in breast cancer patients. Cancer Treat Res Commun. 2023;35:100704.
https://doi.org/10.1016/j.ctarc.2023.100704 DOI: https://doi.org/10.1016/j.ctarc.2023.100704
Eliassen FM, Blåfjelldal V, Helland T, Hjorth CF, Hølland K, Lode L, et al. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer. 2023 July 4;23(1):625.
https://doi.org/10.1186/s12885-023-11122-8 DOI: https://doi.org/10.1186/s12885-023-11122-8
De Jong A, Von Wachenfeldt A, Nyström L, Andersson A. Adherence to adjuvant endocrine therapy after breast cancer in Sweden – a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences. Acta Oncol Stockh Swed. 2024 Nov 24;63:901–8.
https://doi.org/10.2340/1651-226X.2024.40575 DOI: https://doi.org/10.2340/1651-226X.2024.40575
Bright EE, Finkelstein LB, Nealis MS, Genung SR, Wrigley J, Gu HCJ, et al. A systematic review and meta-analysis of interventions to promote adjuvant endocrine therapy adherence among breast cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol. 2023 Oct 1;41(28):4548–61.
https://doi.org/10.1200/JCO.23.00697 DOI: https://doi.org/10.1200/JCO.23.00697
Cucciniello L, Garufi G, Di Rienzo R, Martinelli C, Pavone G, Giuliano M, et al. Estrogen deprivation effects of endocrine therapy in breast cancer patients: incidence, management and outcome. Cancer Treat Rev. 2023 Nov;120:102624.
https://doi.org/10.1016/j.ctrv.2023.102624 DOI: https://doi.org/10.1016/j.ctrv.2023.102624
Yang L, Xue J, Yang Z, Wang M, Yang P, Dong Y, et al. Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2021 May;10(5):5590–9.
https://doi.org/10.21037/apm-21-1096 DOI: https://doi.org/10.21037/apm-21-1096
Di Lauro V, Barchiesi G, Martorana F, Zucchini G, Muratore M, Fontanella C, et al. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. ESMO Open. 2022 Dec;7(6):100629.
https://doi.org/10.1016/j.esmoop.2022.100629 DOI: https://doi.org/10.1016/j.esmoop.2022.100629
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024 Mar 21;390(12):1080–91.
https://doi.org/10.1056/NEJMoa2305488 DOI: https://doi.org/10.1056/NEJMoa2305488
Rugo HS, O’Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022 June;33(6):616–27.
https://doi.org/10.1016/j.annonc.2022.03.006 DOI: https://doi.org/10.1016/j.annonc.2022.03.006
Karihtala P. How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy? Acta Oncol Stockh Swed. 2025 June 25;64:815–29.
https://doi.org/10.2340/1651-226X.2025.43645 DOI: https://doi.org/10.2340/1651-226X.2025.43645
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Ida Christine Jacobsen, Tobias Berg, Maj-Britt Jensen, Ann Søegaard Knop
This work is licensed under a Creative Commons Attribution 4.0 International License.
